Tag: KRAS

Short tandem repeat mutations regulate gene expression in colorectal cancer

A novel STR panel for human protein-coding genes To explore STR mutations in CRC, we first annotated STRs in the introns, exons, and promoter sequence of all protein-coding genes in the GRCh38 reference genome (“Methods”). We discarded STR loci for which genotyping was expected to be inaccurate due to genomic…

Continue Reading Short tandem repeat mutations regulate gene expression in colorectal cancer

cfDNA Extraction Sensitivity Controls – cfDNA Extraction Sensitivity Controls

Does your cfDNA extraction process affect the Limit of Detection (LOD) of a particular gene target? Our new products, cfDNA Extraction Sensitivity Panels and Extraction Low Positive Controls, can help your research and development for liquid biopsy assays. NEW PRODUCTS: cfDNA EXTRACTION SENSITIVITY PANELS &  CONTROLS The Extraction Sensitivity Controls…

Continue Reading cfDNA Extraction Sensitivity Controls – cfDNA Extraction Sensitivity Controls

Can sf3b1 mutation be detected by rflp method?

Can sf3b1 mutation be detected by ARMS-PCR method?5 answersSF3B1 mutations can be detected using the ARMS-ddPCR method, which combines the amplification refractory mutation system (ARMS) with droplet digital polymerase chain reaction (ddPCR). This method allows for the detection of gene mutations at specific sites, including SF3B1 mutations, with high sensitivity…

Continue Reading Can sf3b1 mutation be detected by rflp method?

Spatial, temporal and reversible regulation of endogenous gene in vivo using RNA interference

Abstract RNA interference is a powerful tool for controlling gene expression in mammalian systems; as such, it has become an effective alternative to conventional knockout approaches. RNAi has proven to be an efficient method to inhibit tumor suppressor gene function and yield insight into the important players in cancer biology….

Continue Reading Spatial, temporal and reversible regulation of endogenous gene in vivo using RNA interference

Vulnerabilities Behind Cancer’s “Death Star” Protein Revealed

Researchers at the Centre for Genomic Regulation in Barcelona, Spain, and the Wellcome Sanger Institute have comprehensively identified the allosteric control sites found in the protein KRAS. These are highly sought after targets for drug development, representing secret vulnerabilities, which can be exploited to control the effects of one of…

Continue Reading Vulnerabilities Behind Cancer’s “Death Star” Protein Revealed

Secret vulnerabilities of cancer’s ‘Death Star’ revealed

The study presents the first complete control map for any protein and was published on 18 December in the journal, Nature. KRAS is one of the most frequently mutated genes in cancers of many types. It is found in one in 10 human cancers, with higher prevalence in deadly types…

Continue Reading Secret vulnerabilities of cancer’s ‘Death Star’ revealed

Allosteric Sites Mapped on Key Cancer Protein

Researchers at the Centre for Genomic Regulation and the Wellcome Sanger Institute have comprehensively identified the allosteric control sites found in the protein KRAS, which is one of the most frequently mutated genes in many types of cancer. The scientists used a technology known as deep mutational scanning to quantify…

Continue Reading Allosteric Sites Mapped on Key Cancer Protein

Cancers Death Star Secret Weaknesses Unveiled

Researchers at the Centre for Genomic Regulation in Barcelona, Spain, and the Wellcome Sanger Institute near Cambridge, UK, have comprehensively identified the allosteric control sites found in the protein KRAS. These are highly sought after targets for drug development, representing secret vulnerabilities which can be exploited to control the effects…

Continue Reading Cancers Death Star Secret Weaknesses Unveiled

Experts expose secret weaknesses in ‘undruggable’ cancer’s ‘death star

The KRAS gene is categorized among oncogenes, a class of genes with the capacity to transform healthy cells into cancerous ones when they undergo mutations, according to Medline Plus.  This gene is one of the most frequently mutated genes in cancers of many types. Scientists stated that its presence in…

Continue Reading Experts expose secret weaknesses in ‘undruggable’ cancer’s ‘death star

How To Take Down Cancer’s “Death Star”: New Science Could Let Us Drug The Undruggable

Scientists have discovered new vulnerabilities in a protein that’s often called the “Death Star” of cancer, opening up the possibility of new drugs to target it. This could be a game-changer, as the protein – KRAS – is one of the most frequently mutated cancer proteins, often found in the…

Continue Reading How To Take Down Cancer’s “Death Star”: New Science Could Let Us Drug The Undruggable

A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore | Taiwan News

Targeted therapy regimen, BRAFTOVI® (encorafenib) in combination with cetuximab, included on MOH Cancer Drug List, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer who have received prior systemic therapy. BRAFTOVI in combination with cetuximab has been included on MOH CDL, for patients with BRAFV600E-mutant metastatic colorectal cancer…

Continue Reading A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore | Taiwan News

A STING Operation in neuroendocrine neoplasms | NANETS2023 | NANETS 2023

1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 2University of Minnesota, Minneapolis, MN; 3Caris Life Sciences, Phoenix, AZ; 4The Ohio State University, Columbus, OH; 5Fox Chase Cancer Center, Philadelphia, PA; 6Sylvester Cancer Center, University of Miami, Miami, FL; 7Brown University, Providence, RI Background: Significant advances have been made…

Continue Reading A STING Operation in neuroendocrine neoplasms | NANETS2023 | NANETS 2023

PRRG4 regulates mitochondrial function and promotes migratory behaviors of breast cancer cells through the Src-STAT3-POLG axis | Cancer Cell International

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi.org/10.3322/caac.21660. Article  PubMed  Google Scholar  Hu G, Chong RA, Yang Q, Wei Y, Blanco…

Continue Reading PRRG4 regulates mitochondrial function and promotes migratory behaviors of breast cancer cells through the Src-STAT3-POLG axis | Cancer Cell International

Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma

Whole-genome sequencing (WGS) analysis of early and advanced adenocarcinomas Whole-genome short read and long read sequencing datasets of 76 lung cancer specimens were analyzed. The datasets included newly generated data for 48 early small-sized lung adenocarcinoma cases (collectively called “Early-Ad” hereafter). These cases included 26 AIS (9 and 17 cases…

Continue Reading Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

ABSTRACT Introduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology. Methods: We included exceptional responders and controls with advanced pancreatic cancer from Cleveland Clinic from April 2013 to August…

Continue Reading Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer

Identification of DRGs in PCa Figure 1a showed the flow chart of this study. To explore the role of DRGs in PCa, we analyzed the gene expression profiles of these 15 DRGs in PCa patients. As shown in Fig. 1b, for ACTN4, TLN1, IQGAP1, CD2AP, FLNA, MYH9, MYL6, and ACTB genes, the…

Continue Reading Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer

R ComplexHeatmap – Adujusting the cell size in heatmap

I think the main thing is not to use “width = width/2” in cell_fun1. Using ComplexHeatmap 2.14.0 on R 4.2.1 i was able to modify cell width and height via width and height params in call to Heatmap. I tried a few different widths and heights and each time the…

Continue Reading R ComplexHeatmap – Adujusting the cell size in heatmap

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer -December 13, 2023 at 07:01 am EST

Verastem Oncology announced that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG- 3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC). RAMP 301 is the confirmatory study required by the…

Continue Reading Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer -December 13, 2023 at 07:01 am EST

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON–(BUSINESS WIRE)– Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the…

Continue Reading Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Regulation of the ER-Resident Mannosidase EDEM2 in HEK293 Cells

Abstract EDEM2 plays an important role as the first enzyme that acts during mannose trimming of N-glycosylated proteins in the ERAD machinery. Although EDEM2 expression has been reported to be transcriptionally regulated by the IRE1-sXBP1 pathway, very little is known about how endogenous EDEM2 protein expression is regulated. In this…

Continue Reading Regulation of the ER-Resident Mannosidase EDEM2 in HEK293 Cells

Human Gene Mutation Test Kit Market to witness tremendous growth by 2029 |NuProbe, Integrated DNA Technologies, New England Biolabs, GenScript, CD Genomics

[New York, November 2023] — An insightful market analysis report focusing on the Human Gene Mutation Test Kit Market has just been released by Stats N Data, serving as a valuable resource for both industry leaders and newcomers. This comprehensive report offers a detailed exploration of the global Human Gene…

Continue Reading Human Gene Mutation Test Kit Market to witness tremendous growth by 2029 |NuProbe, Integrated DNA Technologies, New England Biolabs, GenScript, CD Genomics

Analyses Probe into Co-Mutation Activity of Sotorasib in KRAS-Mutant NSCLC

Devika Das, MD Associate Professor UAB Medicine Birmingham, AL LINK TO PART 1 Targeted Oncology: What data support the use of sotorasib (Lumakras) in patients with non–small cell lung cancer (NSCLC) and a KRAS G12C mutation? DEVIKA DAS, MD: The CodeBreaK 100 study [NCT03600883] was a registrational phase 2 study….

Continue Reading Analyses Probe into Co-Mutation Activity of Sotorasib in KRAS-Mutant NSCLC

NOTCH1 mutations predict superior outcomes, NSCLC

Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, and the majority are non-small-cell lung cancer (NSCLC).1,2 Genetic variation is a typical feature of NSCLC that drives cancer initiation and progression.3 Understanding the role of mutated genes in NSCLC is the basis of the development of novel treatment…

Continue Reading NOTCH1 mutations predict superior outcomes, NSCLC

Refubium – Liquid Biopsy – Blood-based biomarkers for the molecular analysis of cancer

Tissue analysis is the current gold standard for cancer diagnosis and characterization, although it may neither fully represent spatial tumor heterogeneity nor clonal evolution under treatment pressure. The analysis of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) holds great potential to partially overcome this limitation. One major uncertainty is,…

Continue Reading Refubium – Liquid Biopsy – Blood-based biomarkers for the molecular analysis of cancer

CIMP Gives The Green Light To Three New Orphan Drugs For Rare Diseases

The Interministerial Commission on Drug Prices (CIPM) proposed at its last meeting in November the total or partial financing of 8 new drugs (three of which are orphan drugs for rare diseases) and 3 new indications for 2 additional drugs, already authorized and previously funded. in other signs. The new…

Continue Reading CIMP Gives The Green Light To Three New Orphan Drugs For Rare Diseases

H101 for cervical cancer | DDDT

Introduction Patients with persistent, recurrent, or metastatic (P/R/M) cervical carcinoma respond poorly to treatment despite the best available therapeutic regimens, with a 5-year survival of 17%.1 Most of them are heavily pretreated with chemotherapy and/or radiotherapy, and many patients experience complications related to treatment or advanced disease, which exclude them…

Continue Reading H101 for cervical cancer | DDDT

Cell-free DNA extraction from urine of lung cancer patients and healthy individuals: Evaluation of a simple method using sample volume up-scaling

Background: Urine holds promise as a source for cell-free DNA (cfDNA) analysis of cancer genetics due to its nature as a self-collectable biospecimen available in large quantities. However, pre-analytical variables such as preservation of cfDNA or efficiency of up-scaling specimen volume need to be better explored to increase analysis sensitivity….

Continue Reading Cell-free DNA extraction from urine of lung cancer patients and healthy individuals: Evaluation of a simple method using sample volume up-scaling

Preliminary Data of MK-1084 +/- Pembrolizumab in Solid Tumors and NSCLC

Carlos Rojas, MD, medical oncology, Centro de Investigacion Clinica, Bradford Hill, discusses preliminary findings from a phase 1 trial (NCT05067283) which evaluated MK-1084, a selective KRAS G12C inhibitor, alone in patients with advanced solid tumors, as well as in combination with pembrolizumab (Keytruda) for the first-line treatment of metastatic non–small…

Continue Reading Preliminary Data of MK-1084 +/- Pembrolizumab in Solid Tumors and NSCLC

Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations

Adams, R. H. & Eichmann, A. Axon guidance molecules in vascular patterning. Cold Spring Harb. Perspect. Biol. 2, a001875 (2010). Article  PubMed  PubMed Central  Google Scholar  Fish, J. E. & Wythe, J. D. The molecular regulation of arteriovenous specification and maintenance. Dev. Dyn. 244, 391–409 (2015). Article  CAS  PubMed  Google…

Continue Reading Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations

Sotorasib and Panitumumab Outperforms SOC in KRAS G12C+ mCRC

Findings from the primary analysis of the phase 3 CodeBreaK 300 trial (NCT05198934) revealed that the combination of sotorasib (Lumakras) at 960 and 240 mg with intravenous (IV) panitumumab (Vectibix) improved progression-free survival (PFS) vs standard-of-care (SOC) in patients with chemorefractory, KRAS G12C-mutated, metastatic colorectal cancer (mCRC).1 With a median…

Continue Reading Sotorasib and Panitumumab Outperforms SOC in KRAS G12C+ mCRC

Biomedicines | Free Full-Text | Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts

1. Introduction Pancreatic ductal adenocarcinoma (PDAC) has one of the highest case-specific mortality rates of all cancers [1]. Although resection remains the only curative therapy for PDAC, improvements in long-term survival are attributable to advances in systemic treatment [2,3,4,5]. Currently, 5-fluorouracil-based (i.e., with irinotecan and oxaliplatin as FOLFIRINOX) or gemcitabine-based…

Continue Reading Biomedicines | Free Full-Text | Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts

Bioinformatics analysis of immune cell infiltration patterns and potential diagnostic markers in atherosclerosis

A database in the Gene Set Enrichment Analysis (GSEA; www.gsea-msigdb.org/gsea/msigdb/index.jsp) platform10,11 was used to identify 134 GLN metabolism-associated genes. Weighted gene co-expression network analysis (WGCNA) and module screening GLN-associated gene sets were investigated using WGCNA. The results demonstrated that when the weighted value was 24 (Fig. 1A), scale independence was greater…

Continue Reading Bioinformatics analysis of immune cell infiltration patterns and potential diagnostic markers in atherosclerosis

Pioneering study finds predictive biomarker in lung adenocarcinoma

In a recent study published in Nature Communications, researchers from the United States of America (USA) investigated the potential of the transcriptome of tumor-adjacent normal lung tissue in predicting the prognosis of lung cancer. They found that molecular profiling of the tumor-adjacent normal (TAN) lung tissue, rather than the tumor…

Continue Reading Pioneering study finds predictive biomarker in lung adenocarcinoma

Whole genome sequencing in high-grade cervical intraepitheli… : Medicine

1. Introduction Cervical cancer (CC) is the third most common cancer in women worldwide and has a high mortality rate among women. In 2008, CC was responsible for 275,000 deaths, thereby being the fourth leading cause of cancer death in females worldwide.[1,2] In China, CC is the second most…

Continue Reading Whole genome sequencing in high-grade cervical intraepitheli… : Medicine

Does microRNA-155 expression predict clinical outcome in myeloproliferative neoplasms?

How does the application route i.v. or i.p. affect the migration of injected CAR T cells. 5 answers Cancer signalling pathway unravelling using bioinformatics 4 answers How does the inherent heterogeneity of solid tumors affect their response to treatment? 5 answers How do T cell subsets influence CAR T cell…

Continue Reading Does microRNA-155 expression predict clinical outcome in myeloproliferative neoplasms?

Unveiling the transcriptomic and epigenetic secrets across 11 tumors

In a recent study published in Nature, researchers created a pan-tumor transcriptomic and epigenetic atlas using single-nucleus chromatin accessibility information and matched ribonucleic acid (RNA)-sequencing data. Study: Epigenetic regulation during cancer transitions across 11 tumour types. Image Credit: ART-ur/Shutterstock.com The researchers studied the spatiotemporal dynamics of chromatin decondensation and transcriptional…

Continue Reading Unveiling the transcriptomic and epigenetic secrets across 11 tumors

The Power of AI: AlphaFold’s Stunning Protein Folding Breakthrough | by Gene Bernardin | Nov, 2023

Image of protein structure from Google DeepMind AlphaFold post. DeepMind’s AlphaFold has once again demonstrated the incredible potential of artificial intelligence. In a new blog post, DeepMind revealed their latest advancements in AlphaFold 2, the AI system for predicting protein structures. The improvements are jaw-dropping. AlphaFold can now predict the…

Continue Reading The Power of AI: AlphaFold’s Stunning Protein Folding Breakthrough | by Gene Bernardin | Nov, 2023

Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Oral and Poster Abstracts 652. Multiple Myeloma: Clinical and Epidemiological: Poster III Research, adult, Translational Research, assays, Plasma Cell Disorders, bioinformatics, Diseases, Lymphoid Malignancies, computational biology, Technology and Procedures, Study Population, Human, molecular testing, omics technologies Dor D. Abelman1,2, Jenna Eagles1*, Stephanie Pedersen1*,…

Continue Reading Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Next generation sequencing uncovers multiple miRNAs associated molecular targets in gallbladder cancer patients

Hundal, R. & Shaffer, E. A. Gallbladder cancer: Epidemiology and outcome. Clin. Epidemiol. 6, 99 (2014). PubMed  PubMed Central  Google Scholar  Lazcano-Ponce, E. C. et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J. Clin. 51(6), 349–364 (2001). Article  CAS  PubMed  Google Scholar  World Health Organization International Agency…

Continue Reading Next generation sequencing uncovers multiple miRNAs associated molecular targets in gallbladder cancer patients

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma

doi: 10.1016/j.lrr.2023.100393. eCollection 2023. Affiliations Expand Affiliations 1 NSW Health Pathology, Liverpool Hospital, Liverpool, NSW 2170, Australia. 2 Ingham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW 2170, Australia. 3 Centre for Circulating Tumour Cell Diagnostics & Research (CCDR) at the Ingham Institute for Applied Medical Research, Liverpool,…

Continue Reading The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma

CRISPR screening in hematology research: from bulk to single-cell level | Journal of Hematology & Oncology

Transcriptomics CROP-seq [46] Jurkat Poly-A CRISPRko Cas9 119 – 5798 (+ 1320 cells with NT gRNA) Lentiviral DROP-seq RNA Perturb-seq [43, 44] K562 Barcode CRISPRi dCas9-KRAB UPR epistasis screen: 9 triplet combinations UPR Perturb-seq experiment: 91 Up to 3 gRNAs in a single vector UPR epistasis screen: 15006 UPR Perturb-seq experiment:…

Continue Reading CRISPR screening in hematology research: from bulk to single-cell level | Journal of Hematology & Oncology

BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

BridgeBio Pharma, Inc. – Presented detailed positive results from the ATTRibute-CM Phase 3 study of acoramidis at the European Society of Cardiology (ESC) Congress, demonstrating that patients survived more and were hospitalized less than has been seen in other interventional studies of transthyretin amyloid cardiomyopathy (ATTR-CM) to the Company’s knowledge,…

Continue Reading BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations

Ethical statement Our research complies with all relevant ethical regulations, including the Declaration of Helsinki and has been approved by the Institutional Review Boards of University of Chicago, Duke University and the Alliance to Cure Cavernous Malformations. Cerebral cavernous malformation lesions All human CCM tissue specimens have been previously reported18,19…

Continue Reading Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations

A glimpse of the next generation of AlphaFold

Progress update: Our latest AlphaFold model shows significantly improved accuracy and expands coverage beyond proteins to other biological molecules, including ligands ‍ Since its release in 2020, AlphaFold has revolutionised how proteins and their interactions are understood. Isomorphic Labs and Google DeepMind have been working together to build the foundations…

Continue Reading A glimpse of the next generation of AlphaFold

The investigation of circRNA profiling reveals the regulatory role of the hsa_circ_0000375/miR-7706 pathway in breast cancer

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623–1649 Article  CAS  PubMed  Google Scholar  Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J et al (2013) Circular RNAs are a large…

Continue Reading The investigation of circRNA profiling reveals the regulatory role of the hsa_circ_0000375/miR-7706 pathway in breast cancer

City of Hope part of successful international

image:  “This is the first Phase 3 clinical trial to show a benefit over standard of care in patients with the KRAS G12C mutation whose cancer progressed after receiving standard chemotherapy. The efficacy results from our study are promising in this population with unmet needs and should set a new…

Continue Reading City of Hope part of successful international

Study identifies promising treatment for advanced colorectal cancer

An international Phase 3 clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab. City of Hope was a participating…

Continue Reading Study identifies promising treatment for advanced colorectal cancer

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Hedrick, S. M., Cohen, D. I., Nielsen, E. A. & Davis, M. M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149–153 (1984). Article  CAS  PubMed  Google Scholar  Yanagi, Y. et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains….

Continue Reading T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology

Patient characteristics and tissue context The clinical interpretation of molecular alterations starts with evaluating relevant patient characteristics and the tissue context in which a genetic profile occurs. The former relates, in particular, to previous therapies, in addition to disease stage and clinical performance status. For example, prior targeted therapies warrant…

Continue Reading NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology

Amgen Announces Data From The Global Phase 3 Codebreak 300 Trial Evaluating Two Doses Of Lumakrasin In Combination With Vectibix -October 22, 2023 at 10:31 am EDT

Oct 22 (Reuters) – Amgen Inc: * AMGEN SAYS CODEBREAK 300 TRIAL WAS STUDIED IN PATIENTS WITH CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER * AMGEN ANNOUNCES DATA FROM THE GLOBAL PHASE 3 CODEBREAK 300 TRIAL EVALUATING TWO DOSES OF LUMAKRASIN IN COMBINATION WITH VECTIBIX * AMGEN SAYS DATA SHOWS STATISTICALLY…

Continue Reading Amgen Announces Data From The Global Phase 3 Codebreak 300 Trial Evaluating Two Doses Of Lumakrasin In Combination With Vectibix -October 22, 2023 at 10:31 am EDT

circRNA poster to be presented at the 30th European Society for Gene and Cell Therapy (ESGCT)

Oslo, Norway, 19 October 2023 – Circio Holding ASA (OSE: CRNA) today announcesthat an abstract describing its circular RNA technology has been accepted forposter presentation at the 30th i European Society for Gene and Cell Therapy inBrussels, Belgium.The poster is scheduled for presentation 25-26 October 2023 and will beavailable on…

Continue Reading circRNA poster to be presented at the 30th European Society for Gene and Cell Therapy (ESGCT)

Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens

Introduction Cancer cells are characterized by unrestrained proliferation and dysregulated growth, which lead to the formation of malignant neoplasms (Hanahan & Weinberg, 2023). The development and progression of cancer have been linked to the dysregulation of multiple signaling pathways, including MAPK/ERK, Wnt/β-catenin, PI3K/AKT/mTOR, and NF-kB, which are among crucial pathways…

Continue Reading Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens

Circio: circRNA poster to be presented at the 30th European Society for Gene and Cell Therapy (ESGCT) -October 19, 2023 at 01:05 am EDT

Oslo, Norway, 19 October 2023 – Circio Holding ASA (OSE: CRNA) today announces that an abstract describing its circular RNA technology has been accepted for poster presentation at the 30th iEuropean Society for Gene and Cell Therapy in Brussels, Belgium. The poster is scheduled for presentation 25-26 October 2023 and…

Continue Reading Circio: circRNA poster to be presented at the 30th European Society for Gene and Cell Therapy (ESGCT) -October 19, 2023 at 01:05 am EDT

Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation

Ioanna Xagoraris a, b, Konstantina Stathopoulou a, Roberta D’ Aulerio c, Minghui He c, Anett Ketscher b, Kenbugul Jatta b, Felix Haglund de Flon b, Gisela Barbany d, Richard Rosenquist d, e, Lisa S. Westerberg c, George Z. Rassidakis a, b, ⁎ a Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden  b Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden  c Department…

Continue Reading Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation

Circio : and Neoregen Biotech enter collaboration for delivery of novel circular RNA therapeutics using NICT technology -October 10, 2023 at 01:04 am EDT

Circio and Neoregen Biotech today announce the start of a research collaboration on novel circular RNA (circRNA) therapeutics based on Circio´s proprietary circVec technology. The parties will test the ability of Neoregen´s NICT (Neoregen Intra-Cellular delivery Technology) delivery system to enhance cellular uptake and nuclear transfer of circVec vectors compared…

Continue Reading Circio : and Neoregen Biotech enter collaboration for delivery of novel circular RNA therapeutics using NICT technology -October 10, 2023 at 01:04 am EDT

Bristol-Myers: Acquisition of Mirati Adds Promising Cancer Drug at a Fair Price

We’re not making significant changes to our $66 Bristol BMY fair value estimate or wide moat rating following the announced $4.8 billion acquisition of cancer-focused biotech Mirati. We believe Mirati’s KRAS G12C inhibitor Krazati is the main driver of the deal. The drug gained approval in second-line non-small cell lung…

Continue Reading Bristol-Myers: Acquisition of Mirati Adds Promising Cancer Drug at a Fair Price

Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects | Biomarker Research

The exploration of methylated biomarkers in plasma for pancreatic cancer is still in its early stages, and the number of studies conducted to date for this purpose is limited. Analysis of cfDNA methylation patterns in pancreatic cancer has been approached both at the whole genome level and by identifying and…

Continue Reading Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects | Biomarker Research

FDA Panel Votes That Phase 3 PFS Data for Sotorasib in KRAS G12C+ Advanced NSCLC Cannot Be Reliably Interpreted

In a 10-to-2 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted that the data for progression-free survival (PFS) per blinded independent central review (BICR) from the phase 3 CodeBreaK 200 trial (NCT04303780) evaluating sotorasib (Lumakras) vs docetaxel for the treatment of patients with pretreated, locally advanced or metastatic KRAS…

Continue Reading FDA Panel Votes That Phase 3 PFS Data for Sotorasib in KRAS G12C+ Advanced NSCLC Cannot Be Reliably Interpreted

BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

In patients treated in the first-line setting (n=20), the confirmed objective response rate (ORR) was 65%, with a 100% disease control rate (DCR) (95% CI: 83.2, 100). In assessable patients in the second-line setting (n=13), the ORR was 54%, with a DCR of 85% (95% CI: 54.6, 98.1). Among patients…

Continue Reading BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

In patients treated in the first-line setting (n=20), the confirmed objective response rate (ORR) was 65%, with a 100% disease control rate (DCR) (95% CI: 83.2, 100). In assessable patients in the second-line setting (n=13), the ORR was 54%, with a DCR of 85% (95% CI: 54.6, 98.1). Among patients…

Continue Reading BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study | BMC Gastroenterology

Tissue samples A total of 84 analytic samples from surgical or biopsy specimens were collected from 84 patients who underwent radical surgery for CRC at Saitama Medical University International Medical Center between January and December 2016. One case was excluded because the specimen was too small; therefore, we used a…

Continue Reading PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study | BMC Gastroenterology

The Nobel Medicine Prize: A Look at the Top Contenders

But Ostman said her guess for this year was on Kevan Shokat, an American biologist who figured out how to block the KRAS cancer gene behind a third of cancers, including challenging-to-treat lung, colon, and pancreatic tumours. T-cell therapy for cancer treatment and work on the human microbiome could also…

Continue Reading The Nobel Medicine Prize: A Look at the Top Contenders

Molecular classification of hormone receptor-positive HER2-negative breast cancer

Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020). Article  PubMed  Google Scholar  Huppert, L. A., Gumusay, O., Idossa, D. & Rugo, H. S. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer….

Continue Reading Molecular classification of hormone receptor-positive HER2-negative breast cancer

Continued CRC Research Informs Later-Line Disease Management

Tumor placement and response to neoadjuvant chemotherapy can help clarify and personalize later-line colorectal cancer (CRC) treatment approaches, according to Howard S. Hochster, MD, FACP, who also emphasized the potential benefits of the paradigm’s expansion to include VEGF inhibitors, such as fruquintinib (HMPL-013). “[Later lines of therapy are] still areas…

Continue Reading Continued CRC Research Informs Later-Line Disease Management

Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype

Background and aims: Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer for which effective therapeutic agents are lacking. Fibroblast growth factor receptor 2 (FGFR2) has become a promising therapeutic target in ICC; however, its incidence and optimum testing method have not been fully assessed. This study investigated the…

Continue Reading Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype

Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment

Patient characteristics In our analysis, we included patients with biliary tract cancer and available comprehensive molecular characterization data from five Austrian cancer centers. The data cut-off date was September 2022 (Fig. 1). Figure 1 Trial design: Flow chart depicting patient allocation. In total, the molecular profile of 159 patients with biliary…

Continue Reading Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment

A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

Patient characteristics and PDX establishment Between February 2016 and July 2020, 787 pediatric, adolescent and young adult patients with recurrent or refractory malignancies were enrolled in the MAPPYACTS trial;2 756 (96%) patients and their parents consented to the optional ancillary study of preclinical model development (Fig. 1a). 744 patients had a…

Continue Reading A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma | Cancer Research

As circRNAs act as miRNA sponges to regulate downstream genes expression (34), we conducted mRNA transcriptome analysis in PANC-1 cells to identify the targets of circARFGEF2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that the JAK–STAT pathway was the most significantly enriched pathway associated with circARFGEF2 (Fig….

Continue Reading Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma | Cancer Research

Next-Generation Sequencing and Lung Cancer Treatment

is the second most common form of cancer and the leading cause of cancer deaths in both men and women in the United States. Advanced-stage lung cancer is usually treated with chemotherapy, a combination of chemo-immunotherapy, immunotherapy, or a targeted agent. Targeted drugs are recommended if your doctor detects the…

Continue Reading Next-Generation Sequencing and Lung Cancer Treatment

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma (HCC) or hepatocholangiocarcinoma (H-CCK) following disease progression on frontline atezolizumab (Tecentriq) and bevacizumab (Avastin) to targeted therapy or another TKI based on identified genomic alterations, according to retrospective findings from a single-center study presented at the 2023…

Continue Reading DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

CircRNA PGAM1 Promotes the Migration and Invasion of Pancreatic Adenocarcinoma Cells by Activating the AKT/mTOR Signaling Pathway

Atay, S. (2020). Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues. PeerJ, 8, e10141. Article  PubMed  PubMed Central  Google Scholar  Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., Global Cancer Statistics, et al. (2021). GLOBOCAN estimates of incidence and mortality worldwide…

Continue Reading CircRNA PGAM1 Promotes the Migration and Invasion of Pancreatic Adenocarcinoma Cells by Activating the AKT/mTOR Signaling Pathway

Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on Results From CodeBreaK 101 Trial

Amgen has initiated a phase 3 study of sotorasib (Lumakras) plus carboplatin and pemetrexed in the first-line treatment of KRASG12C-mutant advanced non–small cell lung cancer (NSCLC) due to results from the CodeBreaK 101 clinical trial (NCT04185883). The results of the study were included as an oral presentation at the International…

Continue Reading Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on Results From CodeBreaK 101 Trial

Genetic Cancer Hereditary Cancer Mutations Susceptibility To Cancer Genetic Changes

Genetic Cancers: Welcome back to “The Science Of Health”, ABP Live’s health column. Last time, in the health column, we discussed the difference between small cell lung cancers and non-small cell lung cancers, and explained why small cell lung cancers are less common than non-small cell lung cancers, despite the…

Continue Reading Genetic Cancer Hereditary Cancer Mutations Susceptibility To Cancer Genetic Changes

Lucence Presses Forward With Favorable Results From Liquid Biopsy Lung Cancer Studies

This article has been updated to provide greater clarity on the comparisons made in the Liquik study. NEW YORK – Precision oncology company Lucence plans to present interim results from the ongoing Liquik liquid biopsy lung cancer study and data pointing toward the potential benefits of cell-free RNA testing for earlier…

Continue Reading Lucence Presses Forward With Favorable Results From Liquid Biopsy Lung Cancer Studies

Role of Super-Enhancers in Triggering Pancreatic Cancer Tumor Growth Explored in Study

NEW YORK — Researchers have identified how gene regulatory regions called super-enhancers can fuel the growth of pancreatic ductal adenocarcinoma (PDAC), which accounts for over 90 percent of all pancreatic cancer cases. In a study published in Nature Communications on Wednesday, a team led by researchers from the Salk Institute…

Continue Reading Role of Super-Enhancers in Triggering Pancreatic Cancer Tumor Growth Explored in Study

TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. Article  PubMed  Google Scholar  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Cancer J Clin. 2020;70(1):7–30. Article  Google Scholar  Thai AA,…

Continue Reading TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway

Ovarian cancer research: five recent breakthroughs

With around 7500 new cases reported in the U.K. alone every year, ovarian cancer may occur because of the inheritance of faulty genes like BRCA. Although the exact reason for cancer-causing genetic mutations is unknown – as with all other kinds of cancer – ovarian cancer research has shown that…

Continue Reading Ovarian cancer research: five recent breakthroughs

SUMOylation of SMAD4 by PIAS1 in Conjunction with Vimentin Upregulation Promotes Migration Potential in Non-Small Cell Lung Cancer

1. Introduction Lung cancer is the most common cancer globally, with 2.21 million cases in 2020 and over 1.8 million deaths from lung cancer, making it the most common cause of cancer-related deaths [1]. In China, the estimated age-standardized incidence rate of lung cancer is as high as 34.8 per…

Continue Reading SUMOylation of SMAD4 by PIAS1 in Conjunction with Vimentin Upregulation Promotes Migration Potential in Non-Small Cell Lung Cancer

“Mouse Modeling of Pancreatic Ductal Adenocarcinoma (PDAC); Search for ” by Kyoko Kojima

Degree Name by School School of Medicine [MED]; Doctor of Philosophy (PhD) Abstract PDAC is a highly malignant neoplasm that carries a very poor prognosis. PDAC development is a multistage transformation process that involves multiple genetic alterations that include activation of EGFR/HER2 and KRAS, and loss-of-function mutations in INK4A/ARF, p53…

Continue Reading “Mouse Modeling of Pancreatic Ductal Adenocarcinoma (PDAC); Search for ” by Kyoko Kojima

Novel epigenetic molecular therapies for imprinting disorders

Surani MA, Barton SC, Norris ML. Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. Nature. 1984;308:548–50. Article  CAS  PubMed  Google Scholar  McGrath J, Solter D. Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell. 1984;37:179–83. Article  CAS  PubMed  Google Scholar  Barlow DP, Stoger…

Continue Reading Novel epigenetic molecular therapies for imprinting disorders

Circio Holding ASA: First half 2023 results -Yesterday at 01:01 am| MarketScreener

Oslo, Norway, 24 August 2023 – Circio Holding ASA (OSE: CRNA),a biotechnology company developing novel circular RNA and immunotherapy medicines, today announces its first half 2023 results. Members of Circio’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below)….

Continue Reading Circio Holding ASA: First half 2023 results -Yesterday at 01:01 am| MarketScreener

Unraveling variant misclassification: Insights from ClinVar and HGMD databases

Cardiac Comprehensive Kit analyzes 292 genes and covers major inherited cardiovascular disorders.   Genes Tested AARS2, ABCA1, ABCC6, ABCC9, ABCG5, ABCG8, ACAD9, ACADVL, ACTA1, ACTA2, ACTC1, ACTN2, ACVR1, ACVR2B, ACVRL1, ADAMTS2, AFF4, AGK, AKAP9, AKT3, ALDH18A1, ALMS1, ALPK3, ANK2, ANKRD1, APOA5, APOB, APOE, ATP6V0A2, ATP6V1A, ATP6V1E1, B3GALT6, B4GALT7, BAG3, BGN,…

Continue Reading Unraveling variant misclassification: Insights from ClinVar and HGMD databases

Impilo Therapeutics Bets on Stroma-Penetrating Platform to Bring Nucleic Acid Therapies to Cancer

NEW YORK – Nucleic acid-based therapies haven’t had much success treating cancer, but newly launched Impilo Therapeutics wants to change that. San Diego-based Impilo, which officially launched this week, aims to develop nucleic acid-based therapies against solid tumors, beginning with a treatment that targets androgen receptor splice variants in patients…

Continue Reading Impilo Therapeutics Bets on Stroma-Penetrating Platform to Bring Nucleic Acid Therapies to Cancer

Engineering Bacteria into Tumor-detecting Biosensors

By Jon Kelvey Colorectal cancer (CRC) remains the fourth leading cause of cancer death worldwide, and while the introduction of widespread screening has reduced mortality, current screening techniques have their drawbacks. While considered the gold standard for detecting precancerous polyps, colonoscopies are invasive procedures, and many people avoid or delay…

Continue Reading Engineering Bacteria into Tumor-detecting Biosensors

Engineered Bacteria Can Detect Tumor DNA

Credit: Dr_Microbe / Getty Images Using CRISPR gene editing, researchers at the University of California, San Diego (UCSD), and colleagues from Australia, have engineered bacteria that can detect the presence of tumor DNA in the colons of mice models, potentially paving the way for biosensors able to identify various diseases….

Continue Reading Engineered Bacteria Can Detect Tumor DNA

Ex vivo expansion of lung cancer-derived disseminated cancer cells from lymph nodes identifies cells associated with metastatic progression

doi: 10.1002/ijc.34658. Online ahead of print. Steffi Treitschke  1 , Kathrin Weidele  1 , Adithi Ravikumar Varadarajan  1 , Giancarlo Feliciello  1 , Jens Warfsmann  1 , Sybille Vorbeck  1 , Bernhard Polzer  1 , Catherine Botteron  1 , Martin Hoffmann  1 , Vadim Dechand  1 , Tobias Mederer  2 , Florian Weber  1   3 , Melanie Werner-Klein  2 , Tobias Robold …

Continue Reading Ex vivo expansion of lung cancer-derived disseminated cancer cells from lymph nodes identifies cells associated with metastatic progression

Genetically modified bacteria can detect cancer in the body

0 Genetically modified bacteria can serve as biosensors and detect cancer in the body. This is reported by a US-Australian research team in relation to colon cancer after experiments on cell cultures and mice. The method is still a long way from clinical use, emphasizes the group led by Susan…

Continue Reading Genetically modified bacteria can detect cancer in the body

Researchers engineer bacteria that can detect tumor DNA

Upper: The bacterium A. baylyi can incorporate DNA from its environment through natural competence. This allows horizontal gene transfer and the integration of cell-free DNA into the A. baylyi genome. Lower: Researchers engineered A. baylyi to find the mutated KRAS gene, which helps colorectal cancers grow. Detection of tumor DNA…

Continue Reading Researchers engineer bacteria that can detect tumor DNA

A cryptic microdeletion del(12)(p11.21p11.23) within an unbalanced translocation t(7;12)(q21.13;q23.1) implicates new candidate loci for intellectual disability and Kallmann syndrome

To date, there have been reports of three balanced translocations and one microdeletion involving 12q24 associated with hypogonadism or KS1,2,3,4. In a case reported in 1983, all three brothers of Vietnamese Chinese origin were found to have severe primary hypogonadism with a karyotype of 46,XY,t(1;12)(p32;q24)3. Another case, published in 1990,…

Continue Reading A cryptic microdeletion del(12)(p11.21p11.23) within an unbalanced translocation t(7;12)(q21.13;q23.1) implicates new candidate loci for intellectual disability and Kallmann syndrome

Leveraging the Full Potential of Sensitive Circulating Tumor DNA Analyses

Credit: eldemir/Getty Images Sponsored content brought to you by Liquid biopsy analyses have redefined the constraints of cancer research, offering a noninvasive approach for the detection and monitoring of mutations critical to characterizing disease status. While pioneered primarily in the field of hematological oncology, liquid biopsy is a highly promising…

Continue Reading Leveraging the Full Potential of Sensitive Circulating Tumor DNA Analyses

Expanding the Drug Target Universe: How Next-Generation Proteomics Is Transforming Oncology Research

Effective target identification and validation lie at the heart of modern drug discovery. Yet the current repertoire of cancer therapeutics is still focused on a relatively small subset of targets compared with the overall “druggable” biology within cancer cells.   Genetic technologies such as genomics and transcriptomics have opened up…

Continue Reading Expanding the Drug Target Universe: How Next-Generation Proteomics Is Transforming Oncology Research

ctDNA and Lung Cancer | SpringerLink

Abbosh C, Birkbak NJ, Wilson GA, et al (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446–451. doi.org/10.1038/nature22364 CrossRef  CAS  PubMed  PubMed Central  Google Scholar  Adalsteinsson VA, Ha G, Freeman SS, et al (2017) Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun…

Continue Reading ctDNA and Lung Cancer | SpringerLink

Streamlining DNA Mutation Detection: A Breakthrough with Phosphorothioated DNA-guided Endonuclease Excision

Challenges in DNA Mutation Detection: Molecular diagnostics of cancer has underscored the significance of driver genetic alterations in tumor growth and metastasis1, 2. Although genetic variations hold abundant diagnostic and therapeutic clues for cancer patients, detecting mutations in cfDNA proves to be a major challenge due to their typically low…

Continue Reading Streamlining DNA Mutation Detection: A Breakthrough with Phosphorothioated DNA-guided Endonuclease Excision

Detection of low-frequency mutations in clinical samples by increasing mutation abundance via the excision of wild-type sequences

Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532 (1988). Article  CAS  PubMed  Google Scholar  Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405–410 (2021). Diaz, L. A. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol….

Continue Reading Detection of low-frequency mutations in clinical samples by increasing mutation abundance via the excision of wild-type sequences

Illumina inks deal to sell Pillar Biosciences’ cancer assays

Illumina has struck a deal to make Pillar Biosciences’ oncology assets commercially available globally as part of its own portfolio. Indianapolis-based Pillar is built on target enrichment chemistry technology that is designed to help reference laboratories and clinical oncology laboratories by automating and accelerating tumor variant detection. The company won…

Continue Reading Illumina inks deal to sell Pillar Biosciences’ cancer assays

IJMS | Free Full-Text | DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers

1. DNA Methylation: Looking Back over the Century “Genes are equivalent to blueprints; epigenetics is the contractor. They change the assembly, the structure.” —Bruce Lipton. The methylation of the DNA is a quintessential epigenetic mechanism consisting of the binding of a methyl group to the fifth carbon of the cytosine…

Continue Reading IJMS | Free Full-Text | DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers

The complementarity of DDR, nucleic acids and anti-tumour immunity

Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. The cGAS–STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548–569 (2021). Article  CAS  PubMed  PubMed Central  Google Scholar  Martincorena, I. & Campbell, P. J. Somatic mutation in cancer and normal cells. Science 349, 1483–1489 (2015)….

Continue Reading The complementarity of DDR, nucleic acids and anti-tumour immunity

Exploring Co-Mutation Patterns Linked to Actionable Drivers in iCCA

The following is a summary of the “Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma,” published in the March 2023 issue of Hepatology by Kendre, et al. For precision oncology in gastrointestinal malignancies, intrahepatic cholangiocarcinoma (iCCA) has emerged as a “role model” in recent years. However, its genetic…

Continue Reading Exploring Co-Mutation Patterns Linked to Actionable Drivers in iCCA

A Liquid Biopsy Study Offers New Hope for Lung Cancer Patients

Published 8 hours ago Submitted by Illumina Photo: From left to right: Charles Janczewski, Chair, Cardiff & Vale University Health Board; Magda Meissner, Project Lead; Eluned Morgan, Minister for Health and Social Services; Sian Morgan, Project Lead | Photo: Life Sciences Hub Wales Originally published on Illumina News Center Lung…

Continue Reading A Liquid Biopsy Study Offers New Hope for Lung Cancer Patients

TScan teams with Tempus to develop companion diagnostic for cancer cell therapy

TScan Therapeutics has partnered with Tempus to develop a companion diagnostic to inform treatment of patients in a clinical trial of its oncology cell therapies. Massachusetts-based TScan is developing T-cell receptor (TCR)-engineered T-cell therapies (TCR-T), for which the biotech firm profiles the tumors of patients and engineers their own T…

Continue Reading TScan teams with Tempus to develop companion diagnostic for cancer cell therapy